600750 Jiangzhong Pharmaceutical
- 25.84
- -0.40-1.52%
Jiangzhong Pharmaceutical News
Zhitong A Share Sale Restriction and Release List | May 30
According to the Zhitong Finance App, the ban on restricted shares of 6 listed companies was lifted on May 30, with a total market value of about 1,908 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Jiangzhong Pharmaceutical's 600,750 shares incentive to sell and circulate 148,000, Midea Group 000333, share incentives, limited sale and circulation, 50436 million, Yi Hualu 300212, corporate placement and listing of 574.591 million Dongxing Medical 301,290, extended sales restrictions and regular circulation 725,000 Xinruida 002983 shares incentive limited circulation 812,000 Pryder 30
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Jiangzhong Pharmaceutical (600750.SH) reported first-quarter results with net profit of 267 million yuan, up 9.99% year on year
According to the Zhitong Finance App, Jiangzhong Pharmaceutical (600750.SH) released its report for the first quarter of 2024, achieving revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%. Net profit attributable to shareholders of listed companies was 267 million yuan, an increase of 9.99% over the previous year. Achieved net profit of 264 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 16.64% over the previous year.
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit in 2023 increased by 708 million yuan year on year, up 18.4% year on year
Gelonghui, March 25, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. Jiangzhong Pharmaceutical (600750.SH) announced its 2023 annual report, with operating revenue of RMB 4.39 billion, up 13.00% year on year; net profit attributable to Jiangzhong Pharmaceutical shareholders of RMB 708 million, up 18.4% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical (after deducting non-recurring income or loss) of 704 million yuan, an increase of 38.97% year on year; basic earnings per share were 1.12 yuan. A cash dividend of 7 yuan is distributed for every 10 shares.
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
Jiang Zhong PharmaceuticalLtd's (SHSE:600750) stock is up by 6.7% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term f
China Resources Pharmaceutical: Jiangzhong Pharmaceutical expects net profit to increase by about 18% year-on-year in 2023
China Resources Pharmaceutical (03320) issued an announcement. According to preliminary accounting by Jiangzhong Pharmaceutical (600750.SH), in 2023, Jiangzhong Pharmaceutical's total revenue increased by about 13% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical increased by about 18% year on year.
Damo: Target price of HK$7.8 for China Resources Pharmaceuticals “gain” rating
Damo released a research report stating that it is believed that the stock price of China Resources Pharmaceuticals (03320) will rise within 30 days, the rating will “increase”, and the target price is HK$7.8. Donga Ejiao (000423.SZ) and Jiangzhong Pharmaceutical (600750.SH), of the five A-share subsidiaries directly under China Resources Pharmaceutical, announced new management incentive plans, all in the form of restricted shares, and both cover profit performance from 2022 to 2026. The bank believes that the management incentive plans of the two companies reflect current expectations that there is room for improvement.
Jiangzhong Pharmaceutical (600750.SH): Proposes to introduce a restricted stock incentive plan of no more than 7.635 million shares
On January 2, Gelonghui Pharmaceutical (600750.SH) announced the second restricted stock incentive plan. It plans to grant no more than 7.635 million restricted shares to incentive recipients, accounting for 1.21% of the company's total share capital when the draft incentive plan was announced. The first incentive was awarded to no more than 213 people, and the award price was 12.79 yuan/share.
Jiangzhong Pharmaceutical (600750.SH): The main sales channel for lumkinase enteric capsules is in primary medical institutions such as level-II hospitals, clinics, health hospitals, etc.
Gelonghui, December 28, 丨 Jiangzhong Pharmaceutical (600750.SH) said on the investor interactive platform that the main sales channels for vermickinase enteric capsules are in primary medical institutions such as level-II hospitals, clinics, health hospitals, etc., and are currently not a type included in national collection. The data disclosed by the company in the regular report “Winning Bids for Major Drugs in Centralized Drug Bidding and Procurement During the Reporting Period” is mainly the online bid winning situation in some provinces, so there is a certain difference from the disclosed data on production volume and sales volume.
Jiangzhong Pharmaceutical (600750.SH): Changes in the shareholding structure of the controlling shareholder
Gelonghui, December 26丨Jiangzhong Pharmaceutical (600750.SH) announced that the corporate shareholders of China Resources Jiangzhong, China Resources Pharmaceutical Holdings, Jiangxi Guogong, and Xinhairunda have signed the “Equity Transfer Agreement”; Xinhairunda transferred 14.4412% of its shares in Huarun Jiangzhong to China Resources Pharmaceutical Holdings and Jiangxi Guocong according to their original relative shareholding ratio in China Resources Jiangzhong, of which it transferred 9.2138% of its shares in Huarun Jiangzhong to Jiangxi Guokong. Equity. China Resources Jiangzhong has already transferred shares in accordance with the above shareholding matters on 2023/12
Jiangzhong Pharmaceutical (600750.SH): Stomach Health and Digestion Tablets Lift Payment Restrictions in the 2023 National Health Insurance Catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui on December 14丨Jiangzhong Pharmaceutical (600750.SH) announced that on December 13, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance” (Health Insurance Development [2023] No. 30) (known as the “2023 National Health Insurance Catalogue”). The company's main product, stomach health and digestion tablets, has been adjusted in the “2023 National Health Insurance Catalogue” and the “children only” payment scope has been lifted.
Is Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Jiang Zhong PharmaceuticalLtd (SHSE:600750) has had a great run on the share market with its stock up by a significant 10% over the last three months. Given that stock prices are usually aligned wit
Jiangzhong Pharmaceutical (600750.SH) distributed 0.6 yuan per share for the first three quarters. The registration date is November 24
Jiangzhong Pharmaceutical (600750.SH) announced that the company will implement equity distribution for the first three quarters of 2023, with each share...
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 589 million yuan in the first three quarters increased 16.74% year-on-year
On October 30, Gelonghui Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (03320.HK) achieved operating income of RMB 3.140 billion in the first three quarters, up 9.24% year on year; net profit attributable to shareholders of listed companies was 589 million yuan, up 16.74% year on year; net profit attributable to shareholders of listed companies was 559 million yuan, up 24.19% year on year. 600750.SH
Jiangzhong Pharmaceutical Unit's Ulcer Drug Passes Regulator's Consistency Evaluation
A drug of Jiangzhong Pharmaceutical (SHA:600750) unit Jincheng Haisi Pharmaceutical, the rabeprazole sodium enteric-coated tablets, passed the quality and efficacy consistency evaluation of China's Na
Jiangzhong Pharmaceutical (600750.SH): Rabeprazole sodium enteric tablets passed the generic drug consistency evaluation
Glonghui, October 19丨Jiangzhong Pharmaceutical (600750.SH) announced that Jincheng Hayes Pharmaceutical Co., Ltd., a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” for rabeprazole sodium enteric tablets (20mg) (“this drug”) approved and issued by the State Drug Administration, approving the drug to pass a consistent evaluation of the quality and efficacy of generic drugs. Rabeprazole sodium enteric tablets are a proton pump inhibitor and are suitable for gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, and Zollinger-Ellison (Zollinger-Ellison) syndrome.
A Look At The Intrinsic Value Of Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Jiang Zhong PharmaceuticalLtd fair value estimate is CN¥20.13 With CN¥18.07 share price, Jiang Zhong PharmaceuticalLtd appears to be trading
Jiangzhong Pharmaceutical (600750.SH): Net profit of 447 million yuan in the first half of the year increased 13.95% year-on-year
Glonghui, August 23, 丨 Jiangzhong Pharmaceutical (600750.SH) announced its semi-annual report. Revenue was 2,298 million yuan, up 20.87% year on year, net profit was 447 million yuan, up 13.95% year on year, net profit was reduced by 414 million yuan, net profit of 414 million yuan, up 16.04% year on year, and basic earnings per share were 0.70 yuan.
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 26% over the past three months, it is easy to disregard Jiang Zhong PharmaceuticalLtd (SHSE:600750). However, stock prices are usually driven by a company's financial performance
Don't Race Out To Buy Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) Just Because It's Going Ex-Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) is about to
Analysis
Price Target
No Data
